GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Nephrology Dialysis Transplantation, Oxford University Press (OUP), Vol. 38, No. 4 ( 2023-03-31), p. 969-981
    Abstract: There is scarce evidence on the fourth dose of severe acute respiratory syndrome coronavirus 2 vaccines in chronic kidney disease (CKD) patients. We evaluated the humoral response and effectivity of the fourth dose in the CKD spectrum: non-dialysis CKD (ND-CKD), haemodialysis (HD), peritoneal dialysis (PD) and kidney transplant (KT) recipients. Methods This is a prespecified analysis of the prospective, observational, multicentric SENCOVAC study. In patients with CKD who had received a complete initial vaccination and one or two boosters and had anti-Spike antibody determinations 6 and 12 months after the initial vaccination, we analysed factors associated with persistent negative humoral response and higher anti-Spike antibody titres as well as the efficacy of vaccination on coronavirus disease 2019 (COVID-19) severity. Results Of 2186 patients (18% KT, 8% PD, 69% HD and 5% ND-CKD), 30% had received a fourth dose. The fourth dose increased anti-Spike antibody titres in HD (P = .001) and ND-CKD (P = .014) patients and seroconverted 72% of previously negative patients. Higher anti-Spike antibody titres at 12 months were independently associated with repeated exposure to antigen (fourth dose, previous breakthrough infections), previous anti-Spike antibody titres and not being a KT recipient. Breakthrough COVID-19 was registered in 137 (6%) patients, 5% of whom required admission. Admitted patients had prior titres & lt;620 UI/ml and median values were lower (P = .020) than in non-admitted patients. Conclusions A fourth vaccine dose increased anti-Spike antibody titres or seroconverted many CKD patients, but those with the highest need for a vaccine booster (i.e. those with lower pre-booster antibody titres or KT recipients) derived the least benefit in terms of antibody titres. Admission for breakthrough COVID-19 was associated with low anti-Spike antibody titres.
    Type of Medium: Online Resource
    ISSN: 0931-0509 , 1460-2385
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2023
    detail.hit.zdb_id: 1465709-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Clinical Kidney Journal, Oxford University Press (OUP), ( 2023-06-29)
    Abstract: Current guidelines establish the same hemoglobin (Hb) and iron biomarkers targets for hemodialysis (HD) and peritoneal dialysis (PD) in patients receiving erythropoiesis-stimulating agents (ESAs) even though patients having PD are usually younger, more active and less comorbid. Unfortunately, specific renal anemia [anemia in chronic kidney disease (aCKD)] trials or observational studies on PD are scanty. The aims of this study were to describe current aCKD management, goals and adherence to clinical guidelines, identifying opportunities for healthcare improvement in PD patients. Methods This was a retrospective, nationwide, multicentre study including patients from 19 PD units. The nephrologists collected baseline data, demographics, comorbidities and data related to anemia management (laboratory values, previously prescribed treatments and subsequent adjustments) from electronic medical records. The European adaptation of KDIGO guidelines was the reference for definitions, drug prescriptions and targets. Results A total of 343 patients (mean age 62.9 years, 61.2% male) were included; 72.9% were receiving ESAs and 33.2% iron therapy [20.7% intravenously (IV)]. Eighty-two patients were receiving ESA without iron therapy, despite 53 of them having an indication according to the European Renal Best Practice guidelines. After laboratory results, iron therapy was only started in 15% of patients. Among ESA-treated patients, 51.9% had an optimal control [hemoglobin (Hb) 10–12 g/dL] and 28.3% between 12–12.9 g/dL. Seventeen patients achieved Hb & gt;13 g/dL, and 12 of them remained on ESA after overshooting. Only three patients had Hb & lt;10 g/dL without ESAs. Seven patients (2%) met criteria for ESA resistance (epoetin dose & gt;300 IU/kg/week). The highest tertile of erythropoietin resistance index ( & gt;6.3 UI/kg/week/g/dL) was associated with iron deficiency and low albumin corrected by renal replacement therapy vintage and hospital admissions in the previous 3 months. Conclusion Iron therapy continues to be underused (especially IV). Low albumin, iron deficiency and prior events explain most of the ESA hyporesponsiveness. Hb targets are titrated to/above the upper limits. Thus, several missed opportunities for adequate prescriptions and adherence to guidelines were identified.
    Type of Medium: Online Resource
    ISSN: 2048-8505 , 2048-8513
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2023
    detail.hit.zdb_id: 2656786-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Elsevier BV ; 2019
    In:  Atención Primaria Vol. 51, No. 6 ( 2019-06), p. 380-381
    In: Atención Primaria, Elsevier BV, Vol. 51, No. 6 ( 2019-06), p. 380-381
    Type of Medium: Online Resource
    ISSN: 0212-6567
    Language: Spanish
    Publisher: Elsevier BV
    Publication Date: 2019
    detail.hit.zdb_id: 2125978-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2023
    In:  Nephrology Dialysis Transplantation Vol. 38, No. Supplement_1 ( 2023-06-14)
    In: Nephrology Dialysis Transplantation, Oxford University Press (OUP), Vol. 38, No. Supplement_1 ( 2023-06-14)
    Abstract: Impaired renal function is one of the most relevant factors associated to crescentic glomerulonephritis (CGN) prognosis. However, renal remission has not yet been defined and clinicians are required to use systemic scores (such as BVAS) to predict severity. In this retrospective study, we aim to describe the associated factors to long-term chronic dialysis incidence and survival in CGN. Method We included all biopsy-proven CGN of our center between 2004 and 2022. At baseline, demographics, treatments and comorbidities were collected. Renal function was assessed by glomerular filtration rate (GFR) using CKD-EPI equation, quantification of proteinuria and demonstration of hematuria. During follow-up (median 1486, interquartile range [25-3082] days) renal and vital status was evaluated. Factors associated to dialysis requirement were assessed using Cox regression models. A combined endpoint of death and dialysis was established. Factors associated to the combined endpoint were assessed. Results We included 47 CGN (77% female, 67±15 years). Of them, 35 (75%) presented positive ANCA antibodies, 3 (6%) positive glomerular basement membrane (GBM) antibodies, 8 (17%) ANCA and GBM antibodies and one (2%) presented negative autoimmunity. Induction treatment was based on prednisone and cyclophosphamide in 43 patients (91%), prednisone and rituximab in 3 (6%) and prednisone alone in one (2%). At admission, median CKD-EPI was 11 (11-21) ml/min/1.73 m2, proteinuria was 1030 (552-1872) mg/g and 43 (91%) patients presented hematuria. Nineteen patients (40%) required dialysis at admission. Following the definition of KDIGO guidelines for renal remission, 28 (64%) patients achieve it at 6 months. During follow-up, fifteen patients (36%) started chronic dialysis. Factors associated to chronic dialysis were the type on CGN (dual ANCA and GBM and GBM (+) vs ANCA (+), p = 0.003), CKD-EPI at admission (p = 0.001), AKIN (p = 0.050), requirement of dialysis at admission (p & lt;0.001), percentage of crescents (p = 0.037), proteinuria at admission (p = 0.046) and remission after induction treatment (p & lt;0.001). Twenty-four patients (53%) died or needed dialysis during follow-up. Factors associated to this combined endpoint were CKD-EPI at admission (p = 0.017), type on CGN (dual ANCA and GBM vs others, p = 0.003) (Figure 1), debut in dialysis (p & lt;0.001), remission after induction treatment (p & lt;0.001). An adjusted Cox regression model demonstrated that the need for dialysis or death during follow-up was independently associated to not achieving remission after induction (i.e. 6 months) (HR 8.78, 95%CI (2.88-26.7), p & lt;0.001) and requirement of dialysis at debut (HR 3.96, 95%CI [1.15-13.6], p = 0.029). Conclusion The requirement of dialysis at debut and not achieving remission after induction are independent predictors of death or need for chronic dialysis in CGN.
    Type of Medium: Online Resource
    ISSN: 0931-0509 , 1460-2385
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2023
    detail.hit.zdb_id: 1465709-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Nephrology Dialysis Transplantation, Oxford University Press (OUP), Vol. 38, No. Supplement_1 ( 2023-06-14)
    Abstract: Urinary parameter determination is an essential tool for differentiating acute kidney injury (AKI) etiology. The most used ion in clinical practice is sodium (and its excretion fraction, NaEF), followed by urea (UreaEF) (that is useful in certain circumstances such as diuretic treatment). However, tubular transport includes other anions and cations that have not been widely studied. In the present study, we aim to evaluate the relation between AKI etiology (i.e. functional vs acute tubular necrosis) and calcium excretion fraction (CaEF). Method This is a transversal study including consecutive patients with diagnosis of AKI. Patients with suspicion of non-functional or ATN etiology (such as those with proteinuria, hematuria) were excluded. At admission, we collected epidemiological data, comorbidities and active treatments. AKI etiology was determined based on urinary parameters (sodium, urea) and recovery pattern of kidney function after treatment instauration. We compared CaEF in patients with ATN and functional AKI in the whole sample and among patients with and without previous CKD and diuretic prescription. Results We included 94 AKI episodes (55% female, 76±15 years). Forty-five (48%) patients had chronic kidney disease (CKD) at baseline and 56 (60%) were receiving treatment with diuretics. Of the 94 AKI, 78 (83%) presented a functional etiology and 16 (17%) were catalogued as ATN. Median CaEF was 1.09 (0.63-2.58) %. CaEF was associated to the etiology of AKI. In patients with functional AKI, median of CaEF was 0.95 (0.60-1.84) % in contrast to ATN (2.33 [1.22-7.27] %)(p & lt;0.001). CaEF presented a positive and significant correlation to NaEF (ρ 0.574, p & lt;0.001) and UreaEF (ρ 0.409, p & lt;0.001). An adjusted regression model including the presence of CKD at baseline and diuretic treatment showed that CaEF independently predicted ATN (OR per 1% increase 1.42, 95%CI [1.16-1.75), p & lt;0.001]. In patients without CKD, CaEF predicted ATN (OR 1.61, 95%CI [1.13-2.28] , p = 0.008), in contrast to the cohort with CKD where only a trend was demonstrated (OR 1.29, 95%CI [0.99-1.69], p = 0.057) (Figure 1). CaEF also predicted ATN irrespective of the diuretic prescription at baseline (OR 1.35, 95%CI [1.05-1.74] , p = 0.018 for diuretic users and OR 1.57, 95%CI [1.06-2.32], p = 0.025 for non-diuretic users) (Figure 1). Receiving operator curves (ROC) demonstrated a 0,712 area under the curve (AUC) of CaEF & gt;1.6% for ATN, that was the best value for diagnosis in terms of sensitivity and specificity. CaEF & gt;1,6% predicted ATN (OR 8.09, 95%CI [2.32-28.2], p = 0.001) after adjusting for the presence of CKD at baseline and diuretic treatment. Conclusion CaEF could help in the identification of the AKI etiology as higher values (i.e. & gt;1.6%) are independently associated with ATN.
    Type of Medium: Online Resource
    ISSN: 0931-0509 , 1460-2385
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2023
    detail.hit.zdb_id: 1465709-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...